About 10–30% of patients with non-small cell lung cancer (NSCLC) harbor mutations, mainly in exons 18–21, of the EGFR gene, which is considered an oncogenic driver [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.